PNCC Selects LotusFlare to Power Digital BSS and Commerce Platform for New 4G/5G Standalone Network
26.2.2026 13:04:00 CET | Business Wire | Press Release
LotusFlare, a provider of a cloud-native, AI-driven digital commerce and monetization platform for communications service providers (CSPs), today announced that Palau National Communications Corporation (PNCC) has selected it to provide a comprehensive commerce and monetization platform, including a full-stack digital business support system (dBSS) as part of PNCC’s broader 4G/5G Standalone (SA) network modernization programme.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226869218/en/
Palau National Communications Corporation (PNCC)
The LotusFlare solution will support PNCC subscribers across mobile, fixed broadband, and digital TV services, while enabling unique multi-tenant capabilities aligned with PNCC’s long-term digital and regional strategy.
PNCC has embarked on a comprehensive technology modernization program focused on increasing speed-to-market, enhancing customer experience, and long-term operational efficiency. After a competitive tender process, PNCC selected LotusFlare for its highly skilled team, cloud-native technology, Internet DNA, and proven experience supporting leading communications service providers globally.
As the national telecommunications operator of the Republic of Palau, PNCC is undertaking a full network transformation to deploy a 4G/5G SA mobile network based on open architecture principles, alongside cloud-native core, OSS, BSS, and digital platforms. The program is designed to improve service agility, enhance network resilience, and support the long-term digital development of Palau.
“PNCC is proving that geographic isolation is no longer a barrier to world-class digital experiences. By utilizing LotusFlare DNO™ Cloud, PNCC is moving beyond legacy limitations to a modern, multi-tenant platform that can serve as a digital blueprint for the entire Pacific region,” said Sam Gadodia, CEO of LotusFlare. “LotusFlare’s expertise and innovative approach will help PNCC deliver valuable business outcomes and enhance the customer experience for the people of Palau.”
Simon Fraser, CEO of PNCC, commented: “Partnering with LotusFlare enables PNCC to deploy a cloud-native digital platform at the core of our new 4G/5G SA network. A modern, API-driven dBSS is fundamental to ensuring agility and enabling the rapid introduction of new digital services for our customers. Geographic isolation or scale should never define digital ambition - the people of Palau deserve world-class connectivity, and this transformation ensures they receive it.“
About PNCC
Palau National Communications Corporation (PNCC) is the national telecommunications provider of the Republic of Palau, delivering mobile, fixed, broadband, and international connectivity services nationwide.
About LotusFlare
Based in Silicon Valley, LotusFlare simplifies technology and customer experience to deliver valuable outcomes for enterprises. The company’s flagship product, DNO™ Cloud, is an AI-driven, cloud-native commerce and monetization platform that serves as a digital Business Support System (BSS) for communications service providers. LotusFlare also owns and operates Nomad eSIM, a global connectivity service providing travelers with convenient, reliable, and affordable data plans in over 200 destinations.
LotusFlare is a trusted partner to leading global enterprises, including Deutsche Telekom, T-Mobile US, A1, Globe Telecom, Liberty Latin America, Singtel, MTN, and TELUS. Learn more at lotusflare.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260226869218/en/
Contacts
LotusFlare Contact
Magdalena Arnautovic
Senior Marketing Manager
Email Address: magdalena.marjanovic@lotusflare.com
LotusFlare News: https://lotusflare.com/news/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Flotusflare.com
%2Fnews%2F&esheet=54434285&newsitemid=20260226869218&lan=en-US&anchor=https%3A%2
F%2Flotusflare.com%2Fnews%2F&index=5&md5=2d1fc1558879b16facd83e51da0b7fa5
LinkedIn: https://www.linkedin.com/company/lotusflare -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.c
om%2Fcompany%2Flotusflare&esheet=54434285&newsitemid=20260226869218&lan=en-US&an
chor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Flotusflare&index=6&md5=6bbc71063
551158f5363b0c154a36e93
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom